Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dimethyl fumarate in secondary progressive multiple sclerosis
2014-003021-18Phase 3Completed
- Sponsor
- Biogen
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in secondary-progressive multiple sclerosis (SPMS) comparing Dimethyl fumarate with Placebo (2 arms). Primary endpoint: Time to disability progression independent of relapse. Started Feb 2015; status: completed.
02
Drugs
dimethyl fumarate
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on 2014-003021-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003021-18.